Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted

被引:69
|
作者
Yamanaka, H [1 ]
Nakajima, M [1 ]
Nishimura, K [1 ]
Yoshida, R [1 ]
Fukami, T [1 ]
Katoh, M [1 ]
Yokoi, T [1 ]
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan
关键词
nicotine; LC-MS/MS; CYP2A6; poor metabolizer;
D O I
10.1016/j.ejps.2004.04.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Generally, 70-80% of absorbed nicotine is mainly metabolized to cotinine by cytochrome P450 (CYP) 2A6. There is genetic polymorphism in the human CYP2A6 gene. Among several mutated alleles, CYP2A6*4 allele is a whole deleted type. The purpose of the present study was to clarify the metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for nicotine and its nine metabolites. Excretion levels of nicotine and its metabolites in 24 h accumulated urine after the chewing of one piece of nicotine gum were evaluated in five Japanese subjects whose CYP2A6 genotype was determined. In three subjects with CYP2A6*1A/CYP2A6*1A, CYP2A6*1A/CYP2A6*1B, and CYP2A6*1A/CYP2A6*4 (group I), nicotine was mainly excreted as cotinine, trans-3'-hydroxycotinine, and their glucuronide (approximately 60%). In contrast, in two subjects with CYP2A6*4/CYP2A6*4 (group II), trace levels of cotinine, cotinine N-glucuronide, and cotinine 1'-N-oxide were detected. Trans-3'-hydroxycotinine and its O-glucuronide were not detected. The excretion levels of nicotine itself, nicotine N-glucuronide, and nicotine 1'-N-oxide were higher than those in the other three subjects. The total excretion levels of these three compounds were approximately 95% in group II versus 35% in group I. However, the sum of the excretion levels of nicotine and all metabolites was similar among these five subjects. This is the first report of the metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:419 / 425
页数:7
相关论文
共 50 条
  • [41] Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6
    Nakajima, M
    Kuroiwa, Y
    Yokoi, T
    DRUG METABOLISM REVIEWS, 2002, 34 (04) : 865 - +
  • [42] Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence
    Malaiyandi, V
    Sellers, EM
    Tyndale, RF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (03) : 145 - 158
  • [43] Dissecting the Association of CYP2A6 With Nicotine Metabolism in African American Smokers
    Pouget, Jennie
    El-Boraie, Ahmed
    Lerman, Caryn
    Knight, Jo
    Cox, Lisa S.
    Nollen, Nikki L.
    Ahluwalia, Jasjit S.
    Chenoweth, Meghan J.
    Tyndale, Rachel F.
    BIOLOGICAL PSYCHIATRY, 2022, 91 (09) : S92 - S93
  • [44] The influence of CYP2A6 polymorphisms and cadmium on nicotine metabolism in Thai population
    Apinan, Roongnapa
    Tassaneeyakul, Wichittra
    Mahavorasirikul, Wiratchanee
    Satarug, Soisangwang
    Kajanawart, Sirimas
    Vannaprasaht, Suda
    Ruenweerayut, Ronnatrai
    Na-Bangchang, Kesara
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2009, 28 (03) : 420 - 424
  • [45] CYP2A6 Polymorphisms May Strengthen Individualized Treatment for Nicotine Dependence
    Akrodou, Yawo Mawuli
    SCIENTIFICA, 2015, 2015 : 1 - 7
  • [46] Nicotine metabolism:: the impact of CYP2A6 on estimates of additive genetic influence
    Swan, GE
    Benowitz, NL
    Lessov, CN
    Jacob, P
    Tyndale, RF
    Wilhelmsen, K
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (02): : 115 - 125
  • [47] Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6
    Yokoi, Tsuyoshi
    DRUG METABOLISM REVIEWS, 2006, 38 : 10 - 11
  • [48] A pilot study characterizing two novel CYP2A6 alleles, CYP2A6*7 and CYP2A6*8, in vivo.
    Xu, C
    Rao, Y
    Xu, B
    Hoffmann, E
    Sellers, EM
    Tyndale, RF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P35 - P35
  • [49] Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme—an in silico approach
    M Rahnasto
    C Wittekindt
    R O Juvonen
    M Turpeinen
    A Petsalo
    O Pelkonen
    A Poso
    G Stahl
    H-D Höltje
    H Raunio
    The Pharmacogenomics Journal, 2008, 8 : 328 - 338
  • [50] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes
    Hiroshi Yamazaki
    Kiyoshi Inoue
    Masafumi Hashimoto
    Tsutomu Shimada
    Archives of Toxicology, 1999, 73 : 65 - 70